Last reviewed · How we verify
Transitional cell carcinoma
Approved treatments
- Imfinzi · AstraZeneca
Imfinzi works by blocking the PD-L1 protein, allowing the immune system to recognize and attack cancer cells. - Imfinzi · University Medical Center Groningen
- Tecentriq · Roche
Tecentriq works by blocking a protein called PD-L1, which helps cancer cells hide from the immune system. - Opdivo · Bristol-Myers Squibb
Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Transitional cell carcinoma patent landscape — cliff calendar, originator estates, attackable patents
- Transitional cell carcinoma treatment landscape brief
- Transitional cell carcinoma treatment updates RSS
Frequently asked questions about Transitional cell carcinoma
What drugs treat Transitional cell carcinoma?
Tracked treatments include Imfinzi, Tecentriq, Opdivo.
What is the treatment for Transitional cell carcinoma?
Standard treatment for Transitional cell carcinoma includes Imfinzi, Tecentriq, Opdivo. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Transitional cell carcinoma patent cliff · Transitional cell carcinoma CI report
- Treatment: Imfinzi · AstraZeneca
- Treatment: Imfinzi · University Medical Center Groningen
- Treatment: Tecentriq · Roche
- Treatment: Opdivo · Bristol-Myers Squibb
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing